Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow. The first patient had progressive disease 18 months post autologous peripheral stem cell transplant. Two and a half months after the initiation of thalidomide therapy extensive new plasmacytomas of the skin and nasal mucosa appeared while the medullary response continued. The second patient was treated with thalidomide for resistant MM. Despite a medullary response he developed neurological signs compatible with cranial nerve involvement and an MRI study was suggestive of a plasmacytoma involving the sellar region. We assume that a change in the expression of some adhesion molecules on the myeloma and/or the stromal cells is responsible for this phenomenon. Treating Physicians should be aware of this phenomenon in MM patients receiving thalidomide.
Avigdor
A
A
Institute of Hematology, the Chaim Sheba Medical Center Tel-Hashomer, Israel. benbasat@post.tau.ac.il
Raanani
P
P
Levi
I
I
Hardan
I
I
Ben-Bassat
I
I
D000328:Adult; D001853:Bone Marrow / Q000473:pathology; D019046:Bone Marrow Neoplasms / Q000473:pathology; D001932:Brain Neoplasms / Q000473:pathology; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology*; D009297:Nasal Mucosa / Q000473:pathology; D009669:Nose Neoplasms / Q000473:pathology; D010954:Plasmacytoma / Q000473:pathology*; D012878:Skin Neoplasms / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects*
D013792:Thalidomide